WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix Inc., today announced the hiring of John Pedersen as CEO and Ken Knudson as Vice President of Global Sales and Marketing. Augmenix is a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy. The company is awaiting FDA clearance of its SpaceOAR® System, the first product in the US to be cleared as a spacer to protect the rectum in men undergoing Prostate Cancer radiotherapy.
John Pedersen joins Augmenix after spending the past two years as Senior Healthcare Advisor for two Healthcare Private Equity Funds – The Gores Group and The Pritzker Group. Prior to this, Mr. Pedersen was President of the Urology and Women’s Health Division at Boston Scientific. During his 15 years at Boston Scientific, he also served as President of the Peripheral Interventions and the Neurovascular Divisions. Prior to Boston Scientific, he was a Senior Engagement Manager at McKinsey & Co.
Mr. Pedersen earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University. He currently serves on the Board of Directors of Therakos and Clinical Innovations, two privately held medical device companies.
Ken Knudson joins Augmenix with 19 years of experience in sales and sales management. Mr. Knudson was previously VP of Global Sales at Cheetah Medical, and US VP of Sales and European VP of Sales at Bard Electrophysiology. Prior to this, he served as Group Director of Sales for the Boston Scientific Urology and Women’s Health Division.
Mr. Knudson earned a BA in Economics from the University of Tennessee and an MBA from Boston University.
“Augmenix completed it Series D fundraising in the Third Quarter of last year and now I am pleased to have John Pedersen and Ken Knudson join the Augmenix team. Their leadership experience in Healthcare and deep knowledge of the Urology market will be invaluable as the company looks forward to the U.S. commercial launch of the SpaceOAR® System for Prostate Cancer”, said Amar Sawhney who will remain as Chairman of the Board of Augmenix.
About Augmenix, Inc.
Augmenix, Inc. is a privately held Company based in Waltham, MA focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups. More information about Augmenix can be found at http://www.Augmenix.com.
Any statements in this news release about future expectations, plans and prospects for Augmenix constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements because of a number of important factors, including the risks that: our development efforts may not be successful, we may not obtain regulatory approval to market any of our products in development and we may not be able to successfully commercialize any products for which we do receive marketing approval. In addition, Augmenix anticipates that subsequent events and developments may cause its views to change. However, while Augmenix may elect to update these forward-looking statements in the future, it specifically disclaims any obligation to do so.